# Enliven Therapeutics, Inc. Common Stock (ELVN)

> Enliven Therapeutics, Inc. Common Stock (ELVN) trades at $46.41 (+3.39%) as of 7:30:05 PM EST on Nov 19, 2026, +10.98% over the past month. Market cap is $3.42B, with 5.7 days to cover in short interest.

Canonical: https://massive.com/quote/elvn
Data as of: 2026-11-20T00:30:05.897Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$46.41** +1.52 (+3.39%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$47.08** +0.67 (+1.44%)
As of 7:30:05 PM EST on Nov 19, 2026 · After hours

## Stock performance

How Enliven Therapeutics, Inc. Common Stock (ELVN) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +3.39% |
| 1W | -3.93% |
| 1M | +10.98% |
| YTD | +201.36% |
| 1Y | +113.38% |
| 52-wk range | $14.79 – $62.32 |

From daily closes through Nov 19, 2026.

## Key statistics

Today's trading snapshot for ELVN: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $44.56 – $46.84 |
| Open | $45.17 |
| Prev close | $44.89 |
| Volume | 993.38K |
| Market cap | $3.42B |
| Shares out | 73.6M |

## Valuation and profitability ratios

Valuation and profitability ratios for Enliven Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 3.77 |
| P/FCF | — |
| ROE | -12.9% |
| ROA | -12.7% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Enliven Therapeutics, Inc. Common Stock (ELVN) insider trading](https://massive.com/quote/elvn/insider-trading.md): open-market Form 4 buys and sells by Enliven Therapeutics, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Enliven Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 5, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 5, 2026, Enliven Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Oct 14, 2026 · Equity compensation grant
  “Additionally, as a new outside director, Ms. Ball was granted stock options to purchase shares of the Company's common stock with a grant date fair value as determined in accordance with U.S. generally accepted accounting principles equal to approximately $650,000. These stock options will vest as to 1/36th of the total number of shares on each monthly anniversary of the grant date, subject to Ms. Ball's continued service through the applicable vesting date.”
- Jun 12, 2026 · Underwriting agreement
  “On June 11, 2026, Enliven Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the "Representatives") of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale in a public offering (the "Offering") of 8,933,334 shares of the Company's common stock.”
- Jun 11, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Encouraging ELVN-001 Efficacy Data by 24 Weeks - Of the 90 patients enrolled in the Phase 1b, 78 had typical BCR::ABL1 transcripts and had at least one post-baseline transcript; 69 patients were evaluable for major molecular response (MMR) by 24 weeks. Overall MMR 54% (n=69) in Phase 1b and 61% (n=28) in Phase 1b 80 mg QD Cohort.”
- Jun 10, 2026 · Annual meeting results
  “Enliven Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on June 9, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Proposal 1: Election of Two Class III Directors... Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm... Proposal 3: Amendment to the Amended and Restated Certificate of Incorporation... Proposal 4: Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers... Proposal 5: Approval, in an Advisory (Non-Binding) Vote, of the Frequency of Future Stockholder Advisory Votes on the Compensation of the Company's Named Executive Officers”

## ELVN short interest

How heavily ELVN is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 5.7 |
| Short interest | 10.29M |
| Avg volume | 1.81M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ELVN news

The latest news and headlines about Enliven Therapeutics, Inc. Common Stock (ELVN).

- [Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain \| DelveInsight](https://www.globenewswire.com/news-release/2026/09/08/3358009/0/en/chronic-myeloid-leukemia-clinical-trial-pipeline-appears-robust-with-25-key-pharma-companies-actively-working-in-the-domain-delveinsight.html) · GlobeNewswire Inc. · Sep 8, 2026 · positive sentiment
- [What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally](https://www.fool.com/coverage/filings/2026/06/27/what-to-know-about-orbimed-s-usd39-million-enliven-therapeutics-stock-sale-amid-a-130-rally/?source=iedfolrf0000001) · The Motley Fool · Jun 27, 2026 · neutral sentiment
- [Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?](https://www.fool.com/coverage/filings/2026/06/24/medical-hedge-fund-sells-281-000-shares-of-enliven-theapeutics-is-it-time-to-sell-elvn/?source=iedfolrf0000001) · The Motley Fool · Jun 24, 2026 · neutral sentiment
- [Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.](https://www.fool.com/coverage/filings/2026/06/01/enliven-therapeutics-chief-medical-officer-sold-5-000-company-shares-here-s-what-that-means-for-investors/?source=iedfolrf0000001) · The Motley Fool · Jun 1, 2026 · neutral sentiment
- [Enliven Posts Loss Beat and Cash Surge](https://www.fool.com/data-news/2025/08/13/enliven-posts-loss-beat-and-cash-surge/?source=iedfolrf0000001) · The Motley Fool · Aug 13, 2025 · positive sentiment

## About Enliven Therapeutics, Inc. Common Stock

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 65 |
| Listed | Feb 24, 2023 |

[Company website](https://www.enliventherapeutics.com)

## FAQ

### What is the Enliven Therapeutics, Inc. Common Stock (ELVN) stock price today?

Enliven Therapeutics, Inc. Common Stock (ELVN) is trading at $46.41 (+3.39% on the day) as of 7:30:05 PM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Enliven Therapeutics, Inc. Common Stock?

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the…

### What is the short interest in ELVN?

As of Oct 30, 2026, ELVN has 10.29M shares short and 5.7 days to cover.

### What exchange is ELVN listed on?

Enliven Therapeutics, Inc. Common Stock (ELVN) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ELVN quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ELVN`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Enliven Therapeutics, Inc. Common Stock (ELVN) insider trading](https://massive.com/quote/elvn/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
